Canagliflozin ― something new for type 2 diabetes, but is it safe and efficacious?DOGGRELL, Sheila A; MCINTYRE, Kerry.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 3, pp 437-441, issn 1465-6566, 5 p.Article

Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysisYANG, Xu-Ping; DAN LAI; ZHONG, Xiao-Yan et al.European journal of clinical pharmacology. 2014, Vol 70, Num 10, pp 1149-1158, issn 0031-6970, 10 p.Article

Canagliflozin, a Novel SGLT2 Inhibitor for Treatment of Type 2 DiabetesNIGRO, Stefanie C; RICHE, Daniel M; PHENG, Michelle et al.The Annals of pharmacotherapy. 2013, Vol 47, Num 10, pp 1301-1311, issn 1060-0280, 11 p.Article

Safety of Canagliflozin in Patients with Type 2 DiabetesMIKHAIL, Nasser.Current drug safety (Print). 2014, Vol 9, Num 2, pp 127-132, issn 1574-8863, 6 p.Article

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studiesNYIRJESY, Paul; SOBEL, Jack D; FUNG, Albert et al.Current medical research and opinion. 2014, Vol 30, Num 6, pp 1109-1119, issn 0300-7995, 11 p.Article

Canagliflozine pour traiter le diabète de type 2 = Canagliflozine for type 2 diabetesThe Medical letter on drugs and therapeutics (Edition française). 2013, Vol 35, Num 12, pp 45-47, issn 0253-8512, 3 p.Article

Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy ParticipantsDEVINENI, Damayanthi; VACCARO, Nicole; POLIDORI, David et al.Clinical therapeutics. 2014, Vol 36, Num 5, pp 698-710, issn 0149-2918, 13 p.Article

Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors—Fighting Diabetes from a New PerspectiveANGELOPOULOS, Theodoros P; DOUPIS, John.Advances in therapy. 2014, Vol 31, Num 6, pp 579-591, issn 0741-238X, 13 p.Article

The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Type 2 Diabetes MellitusTAYLOR, Shawn Riser; HARRIS, Kira B.Pharmacotherapy. 2013, Vol 33, Num 9, pp 984-999, issn 0277-0008, 16 p.Article

Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes MellitusPLOSKER, Greg L.Drugs (Basel). 2014, Vol 74, Num 7, pp 807-824, issn 0012-6667, 18 p.Article

Canagliflozin, a new sodium―glucose cotransporter 2 inhibitor, in the treatment of diabetesNISLY, Sarah A; KOLANCZYK, Denise M; WALTON, Alison M et al.American journal of health-system pharmacy. 2013, Vol 70, Num 4, pp 311-319, issn 1079-2082, 9 p.Article

Canagliflozin: First Global ApprovalELKINSON, Shelley; SCOTT, Lesley J.Drugs (Basel). 2013, Vol 73, Num 9, pp 981-990, issn 0012-6667, 10 p.Article

canagliflozine ^(INVOKANA°): Me-too de la trop dangereuse dapagliflozineLa Revue Prescrire. 2014, Vol 34, Num 372, pp 733-736, issn 0247-7750, 4 p.Article

New and Emerging Pharmacologic Therapies for Type 2 Diabetes, Dyslipidemia, and Obesity : Diabetes Update in Clinical TherapeuticsTAYLOR, James R; DIETRICH, Eric; POWELL, Jason G et al.Clinical therapeutics. 2013, Vol 35, Num 1, issn 0149-2918, A3-A17Article

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetesPOLIDORI, David; MARI, Andrea; FERRANNINI, Ele et al.Diabetologia (Berlin). 2014, Vol 57, Num 5, pp 891-901, issn 0012-186X, 11 p.Article

Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III studyINAGAKI, Nobuya; KONDO, Kazuoki; YOSHINARI, Toru et al.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 11, pp 1501-1515, issn 1465-6566, 15 p.Article

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialLAVALLE-GONZALEZ, F. J; JANUSZEWICZ, A; DAVIDSON, J et al.Diabetologia (Berlin). 2013, Vol 56, Num 12, pp 2582-2592, issn 0012-186X, 11 p.Article

Cerebrovascular Accident in a High-Risk Patient During the Early Initiation Phase With CanagliflozinFOUSHEE, Jaime A; GOODBAR, Nancy H; KELLY, Jason L et al.The Annals of pharmacotherapy. 2014, Vol 48, Num 8, pp 1066-1069, issn 1060-0280, 4 p.Article

Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidenceSCHEEN, A. J; PAQUOT, N.Diabetes & metabolism. 2014, Vol 40, Num DEC, issn 1262-3636, S4-S11, SUP1Article

Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in DiabetesDE NICOLA, Luca; GABBAI, Francis B; LIBERTI, Maria Elena et al.American journal of kidney diseases. 2014, Vol 64, Num 1, pp 16-24, issn 0272-6386, 9 p.Article